BidaskClub Lowers Grifols SA, Barcelona (GRFS) to Hold

Grifols SA, Barcelona (NASDAQ:GRFS) was downgraded by stock analysts at BidaskClub from a “buy” rating to a “hold” rating in a report released on Saturday.

Other equities research analysts have also issued research reports about the company. Citigroup began coverage on Grifols SA, Barcelona in a research note on Tuesday, October 31st. They set a “buy” rating on the stock. Zacks Investment Research downgraded Grifols SA, Barcelona from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Finally, UBS Group downgraded Grifols SA, Barcelona from an “outperform” rating to a “market perform” rating in a research report on Friday, November 24th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $24.00.

Shares of Grifols SA, Barcelona (GRFS) traded down $0.14 during trading hours on Friday, hitting $24.08. The stock had a trading volume of 768,317 shares, compared to its average volume of 507,713. The stock has a market cap of $16,537.97, a price-to-earnings ratio of 25.89, a price-to-earnings-growth ratio of 1.62 and a beta of 1.05. The company has a debt-to-equity ratio of 1.69, a current ratio of 3.17 and a quick ratio of 1.39. Grifols SA, Barcelona has a fifty-two week low of $16.70 and a fifty-two week high of $25.09.

Grifols SA, Barcelona (NASDAQ:GRFS) last announced its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported $0.29 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.29. Grifols SA, Barcelona had a return on equity of 18.08% and a net margin of 13.16%. sell-side analysts expect that Grifols SA, Barcelona will post 1.17 EPS for the current year.

Several institutional investors have recently modified their holdings of the stock. Harding Loevner LP raised its position in shares of Grifols SA, Barcelona by 477.5% during the 3rd quarter. Harding Loevner LP now owns 89,561,714 shares of the biotechnology company’s stock worth $272,368,000 after purchasing an additional 74,051,933 shares during the last quarter. FMR LLC raised its position in shares of Grifols SA, Barcelona by 2.7% during the 2nd quarter. FMR LLC now owns 6,523,773 shares of the biotechnology company’s stock worth $137,847,000 after purchasing an additional 171,192 shares during the last quarter. Vaughan Nelson Investment Management L.P. raised its position in shares of Grifols SA, Barcelona by 3.4% during the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 2,829,561 shares of the biotechnology company’s stock worth $61,939,000 after purchasing an additional 91,990 shares during the last quarter. Ameriprise Financial Inc. raised its position in shares of Grifols SA, Barcelona by 8.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 2,054,762 shares of the biotechnology company’s stock worth $44,958,000 after purchasing an additional 153,563 shares during the last quarter. Finally, First Trust Advisors LP raised its position in shares of Grifols SA, Barcelona by 14.3% during the 3rd quarter. First Trust Advisors LP now owns 1,810,900 shares of the biotechnology company’s stock worth $39,641,000 after purchasing an additional 226,245 shares during the last quarter. Hedge funds and other institutional investors own 22.50% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “BidaskClub Lowers Grifols SA, Barcelona (GRFS) to Hold” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. & international copyright law. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/01/20/bidaskclub-lowers-grifols-sa-barcelona-grfs-to-hold.html.

Grifols SA, Barcelona Company Profile

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.

Receive News & Ratings for Grifols SA Barcelona Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols SA Barcelona and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply